Anti-Human PD-1 Antibody (34067)

Product No.: 34067

- -
- -
Clone
G001.1
Target
PD-1
Formats AvailableView All
Product Type
Monoclonal
Alternate Names
Protein PD-1, hPD-1, CD antigen CD279
Isotype
Mouse IgG2b
Applications
IHC

- -
- -
Select Product Size

Data

Immunohistochemistry: Detection of PD-1 in human tonsil with #34067 diluted 1:100-1:200.
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Immunogen
Recombinant human PD-1.
Formulation
Tris buffer, pH 7.3-7.7, 1% BSA, 0.1% sodium azide.
State of Matter
Liquid
Product Preparation
Purified by immunoaffinity chromatography
Storage and Handling
Store at 2-8°C. Do not freeze.
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco


Immunohistochemistry: use at a dilution of 1:100-1:200 on formalin-fixed, paraffin-embedded samples after heat-induced epitope retrieval at pH 9 for 10-30 minutes.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Mouse Monoclonal Antibody specific to PD-1
Background
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumor immunity as PD-L1 has been shown to induce apoptosis of activated T-cells or inhibit activity of cytotoxic T-cells. In comparison to CD10 and bcl-6, PD-1 is expressed by fewer B- cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non–small cell lung cancer, melanoma, and renal-cell cancer.
Function
Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed:21276005). Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed:21276005). Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (By similarity). {UniProtKB:Q02242, PubMed:21276005}.; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28951311). The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed:28951311). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed:22658127, PubMed:25034862, PubMed:25399552). {PubMed:22658127, PubMed:25034862, PubMed:25399552, PubMed:28951311}.
NCBI Gene Bank ID
UniProt.org
Research Area
Cancer Research

References & Citations

Formats Available

- -
- -
Prod No.
Description
34067
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.